SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase
In recent months Novo Nordisk has invested several billions of dollars to boost its manufacturing capacity—including its highly contested $16.5 billion merger with CDMO giant Catalent.
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Business
Previous Investment Patterns Set to Repeat in 2025
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss how a slow and steady pace is a continuation of the pattern we have seen throughout the last three years.
December 5, 2024
 · 
1 min read
 · 
Lori Ellis
Illustration showing hurdles along a path ending in an arrow
Policy
How Trump’s Immigration Policies Could Affect Biopharma Professionals’ Work Visas
Based on how President-elect Donald Trump’s first administration handled immigration, experts are concerned about how his second term will impact foreign-born biopharma professionals. Two immigration attorneys discuss what may be ahead, including increased difficulty getting work visas.
December 5, 2024
 · 
6 min read
 · 
Angela Gabriel
GSK's headquarters office building in Poznan, Poland
ADCs
GSK Turns Back to China in Another Potential $1B+ ADC Deal
One year after a potential $1.7 billion deal with Hansoh Pharma, GSK goes back to China to forge another alliance with DualityBio for another deal that could be worth up to $1 billion as it continues to build up its ADC portfolio.
December 4, 2024
 · 
1 min read
 · 
Kate Goodwin
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Series A
Obesity-Focused Antag Debuts With $84M and Backing From Novo Holdings
The Danish startup, whose lead candidate has parallels to Amgen’s MariTide, launches on the heels of Amgen’s Phase II data release for the drug last week.
December 4, 2024
 · 
2 min read
 · 
Heather McKenzie
Closeup Benjamin Franklin face on USD banknote with stock market chart graph and United States flag for currency exchange and global trade forex concept.
Policy
Trump Administration a Mixed Bag for Biopharma
President-elect Donald Trump and his incoming administration are unlikely to attempt a wholesale restructuring of U.S. healthcare and could promote M&A activity, but controversial picks like Robert F. Kennedy could impact vaccine sales, experts say.
December 4, 2024
 · 
3 min read
 · 
Annalee Armstrong
Pictured: Eli Lilly's headquarters in Indianapolis
Obesity
Lilly Claims Key Weight Loss Victory Over Novo in Head-to-Head Study
SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in stronger weight loss than semaglutide.
December 4, 2024
 · 
3 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
 · 
2 min read
 · 
Tristan Manalac
3D illustration of tow GLP-1 therapy autoinjectors
Weight loss
Amylin Commands Weight Loss Attention as Industry Anticipates Novo’s Phase III CagriSema Readout
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight loss with a cleaner tolerability profile.
December 4, 2024
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS